Hovik O, et al. - Researchers undertook this prospective observational study with total joint arthroplasty patients to compare complication rates between patients using either low-dose aspirin (75 mg once daily) or low-molecular-weight heparin (LMWH; Fragmin/dalteparin 5000 U) for venous thromboembolism (VTE) prophylaxis. This analysis involved all total hip or knee arthroplasties from 2014 to 2020. In the aspirin group, 0.28% deep venous thrombosis (DVT) and 0.28% pulmonary embolism (PE) was estimated, and the LMWH group had 0.24% DVT and 0.16% PE. There was no difference in deep infection, allogenic blood transfusion, or mortality. Findings revealed that the observed complication rates did not differ statistically significantly between aspirin 75 mg and LMWH used for VTE prophylaxis. The results also demonstrated the safety of aspirin 75 mg administered daily for VTE prevention post- total hip or knee arthroplasty.